FR2848210B1 - Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases - Google Patents

Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases

Info

Publication number
FR2848210B1
FR2848210B1 FR0215428A FR0215428A FR2848210B1 FR 2848210 B1 FR2848210 B1 FR 2848210B1 FR 0215428 A FR0215428 A FR 0215428A FR 0215428 A FR0215428 A FR 0215428A FR 2848210 B1 FR2848210 B1 FR 2848210B1
Authority
FR
France
Prior art keywords
alkyl
halo
conr6r7
tet
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0215428A
Other languages
English (en)
French (fr)
Other versions
FR2848210A1 (fr
Inventor
Maxime Lampilas
Branislav Musicki
Michel Klich
David Alan Rowlands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entasis Therapeutics Ltd
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0215428A priority Critical patent/FR2848210B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to DE60323135T priority patent/DE60323135D1/de
Priority to KR1020057010234A priority patent/KR101146802B1/ko
Priority to EP03789523A priority patent/EP1569935B1/fr
Priority to PCT/FR2003/003523 priority patent/WO2004052891A1/fr
Priority to CA2507607A priority patent/CA2507607C/fr
Priority to AU2003294104A priority patent/AU2003294104A1/en
Priority to AT03789523T priority patent/ATE405567T1/de
Priority to JP2004558137A priority patent/JP4954477B2/ja
Priority to US10/727,911 priority patent/US7439253B2/en
Publication of FR2848210A1 publication Critical patent/FR2848210A1/fr
Application granted granted Critical
Publication of FR2848210B1 publication Critical patent/FR2848210B1/fr
Priority to US12/211,509 priority patent/US20090018329A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR0215428A 2002-12-06 2002-12-06 Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases Expired - Fee Related FR2848210B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0215428A FR2848210B1 (fr) 2002-12-06 2002-12-06 Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
JP2004558137A JP4954477B2 (ja) 2002-12-06 2003-11-28 新規複素環化合物、それらの調製、ならびに薬剤として、特に抗菌剤およびβ−ラクタマーゼ阻害剤としてのそれらの使用
EP03789523A EP1569935B1 (fr) 2002-12-06 2003-11-28 Composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
PCT/FR2003/003523 WO2004052891A1 (fr) 2002-12-06 2003-11-28 Composes heterocyclique, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
CA2507607A CA2507607C (fr) 2002-12-06 2003-11-28 Composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
AU2003294104A AU2003294104A1 (en) 2002-12-06 2003-11-28 Heterocyclic compounds, preparation method thereof and use of same as medicaments, such as anti-bacterial medicaments and beta-lactamase inhibitors
DE60323135T DE60323135D1 (de) 2002-12-06 2003-11-28 Heterozyklische verbindungen, ihre herstellung und ihre therapeutische verwendung, besonders als antibakterielle und beta-lactamase inhibitoren
KR1020057010234A KR101146802B1 (ko) 2002-12-06 2003-11-28 헤테로사이클릭 화합물, 그 제조방법, 및 항균 약제 및베타-락타메이즈 저해제와 같은 약제로서의 그 용도
AT03789523T ATE405567T1 (de) 2002-12-06 2003-11-28 Heterozyklische verbindungen, ihre herstellung und ihre therapeutische verwendung, besonders als antibakterielle und beta-lactamase inhibitoren
US10/727,911 US7439253B2 (en) 2002-12-06 2003-12-04 Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US12/211,509 US20090018329A1 (en) 2002-12-06 2008-09-16 Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215428A FR2848210B1 (fr) 2002-12-06 2002-12-06 Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases

Publications (2)

Publication Number Publication Date
FR2848210A1 FR2848210A1 (fr) 2004-06-11
FR2848210B1 true FR2848210B1 (fr) 2007-10-19

Family

ID=32320045

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0215428A Expired - Fee Related FR2848210B1 (fr) 2002-12-06 2002-12-06 Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases

Country Status (9)

Country Link
EP (1) EP1569935B1 (https=)
JP (1) JP4954477B2 (https=)
KR (1) KR101146802B1 (https=)
AT (1) ATE405567T1 (https=)
AU (1) AU2003294104A1 (https=)
CA (1) CA2507607C (https=)
DE (1) DE60323135D1 (https=)
FR (1) FR2848210B1 (https=)
WO (1) WO2004052891A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
WO2007065288A2 (en) 2005-12-07 2007-06-14 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
FR2914923B1 (fr) * 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
RU2614418C2 (ru) * 2012-08-25 2017-03-28 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
JP6764862B2 (ja) * 2014-11-17 2020-10-07 エンタシス・セラピューティックス・リミテッド 耐性細菌感染症の治療のための併用療法
DK3512851T3 (en) 2016-09-16 2022-10-17 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
WO2018208769A1 (en) 2017-05-08 2018-11-15 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
EP3604309A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3604315A1 (en) * 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN115151544B (zh) 2020-09-01 2024-08-16 宁夏农林科学院 β-内酰胺酶抑制剂及其制备
CN115605480B (zh) 2021-05-07 2024-04-05 宁夏农林科学院 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
WO2024227071A1 (en) * 2023-04-26 2024-10-31 Entasis Therapeutics Limited Synthesis of durlobactam

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676230B1 (fr) * 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
CZ282567B6 (cs) * 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
EP1091944A1 (en) * 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
CO5180550A1 (es) * 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Also Published As

Publication number Publication date
KR101146802B1 (ko) 2012-05-21
AU2003294104A1 (en) 2004-06-30
JP2006512335A (ja) 2006-04-13
WO2004052891A8 (fr) 2005-07-28
EP1569935A1 (fr) 2005-09-07
JP4954477B2 (ja) 2012-06-13
KR20050088302A (ko) 2005-09-05
EP1569935B1 (fr) 2008-08-20
ATE405567T1 (de) 2008-09-15
CA2507607A1 (fr) 2004-06-24
DE60323135D1 (de) 2008-10-02
WO2004052891A1 (fr) 2004-06-24
FR2848210A1 (fr) 2004-06-11
CA2507607C (fr) 2014-06-17

Similar Documents

Publication Publication Date Title
FR2848210B1 (fr) Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
HUP0400467A2 (hu) 2-Iminopirrolidin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2004516293A5 (https=)
CA2444634A1 (en) Spiropyrazole compounds
CA2545427A1 (en) Selective kinase inhibitors
HUP0300382A2 (hu) 2-Szubsztituált-4-heteroaril-pirimidinek és alkalmazásuk proliferatív rendellenességek kezelésében és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0104816A2 (hu) 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra
JP2009518317A5 (https=)
TR200400185T4 (tr) PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri.
HUP0400558A2 (hu) Helyettesített benzolszármazékok, illetve sóik és ezeket tartalmazó gyógyszerkészítmények
EA200500474A1 (ru) Производные хинолилпропилпиперидина и их применение в качестве антимикробных средств
NO982901D0 (no) Nye barbitursyrederivater, fremgangsmÕter for fremstilling av slike, samt farmas°ytiske midler inneholdende disse forbindelser
SE0101579D0 (sv) New compounds
MA33501B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
CO4950515A1 (es) Nuevos derivados de la quinolina para uso medicinal
HUP0001396A2 (hu) 3-Amino-3 aril-propán-1-ol-származékok, előállításuk és felhasználásuk
NO964698D0 (no) Bicykliske aminderivater som inhibitorer av nitrogenoksid-syntetase
RU2009140730A (ru) Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
PT1242402E (pt) Novos compostos
ATE234305T1 (de) Dihydrofuro-(3,4-b)-chinolein-1-on derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
AR015445A1 (es) Metodo para preparar un compuesto derivado de quinolina, dichos compuestos y compuestos intermediarios
CO5261560A1 (es) Nuevos derivados de tiazolidindiona como agentes antidiabeticos
DK1050531T3 (da) Pyridin- og piperidinderivater til behandling af neurodegenerative sygdomme
BRPI0509564A (pt) derivados pirrolo(2,3-b)piridina, respectivo preparo e respectiva utilização farmacêutica como inibidores de quinases

Legal Events

Date Code Title Description
CA Change of address
TP Transmission of property
PLFP Fee payment

Year of fee payment: 14

TP Transmission of property

Owner name: ENTASIS THERAPEUTICS LIMITED, GB

Effective date: 20160217

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20180831